
Lantern Pharma Inc.'S (NASDAQ: LTRN) AI-Powered Platform Delivers Promising And Durable Results In Lung Cancer Trial
(MENAFN- Investor Brand Network) Lantern Pharma uses a proprietary AI platform, RADR®, to guide its oncology drug development, enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data. A Phase 2 trial …